TimothyGBeukelmanMD
Pediatric Rheumatology • Birmingham, ALAssistant Professor, Pediatrics, University of Alabama School of Medicine
Are you Dr. Beukelman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 94 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1600 7th Ave S
Birmingham, AL 35233Phone+1 205-638-9438
Summary
- Dr. Timothy Beukelman, MD is a pediatric rheumatologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama, Florida, and Pennsylvania. He is affiliated with Children's of Alabama and University of Alabama Hospital.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Rheumatology, 2004 - 2007
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 2001 - 2004
Washington University in St. Louis School of MedicineClass of 2001
Certifications & Licensure
AL State Medical License 2007 - 2021
FL State Medical License 2013 - 2015
PA State Medical License 2004 - 2008
OH State Medical License 2001 - 2005
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry Start of enrollment: 2015 Jul 01
Publications & Presentations
PubMed
- Generating Real-World Evidence From the Excellence Network in Rheumatology.Timothy Beukelman, Amy Mudano, Patrick Stewart, Shilpa Venkatachalam, Fenglong Xie
Pharmacoepidemiology and Drug Safety. 2024-12-01 - Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Cours...Melissa L Mannion, Shahla Amin, Stephen Balevic, Min-Lee Chang, Colleen K Correll
Arthritis Care & Research. 2024-08-01 - Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis.Kyoko Saito, Avinash Gabbeta, Evan Mulvihill, Lina Al-Jaberi, Timothy Beukelman
Pharmacoepidemiology and Drug Safety. 2024-05-01
Press Mentions
- For Systemic JIA, Start Biologics EarlyNovember 10th, 2021
- Methotrexate Use Varies Significantly Prior to Etanercept in Juvenile Idiopathic ArthritisSeptember 8th, 2021
Anakinra Effective in Pediatric Secondary Hemophagocytic LymphohistiocytosisMarch 11th, 2020- Join now to see all
Professional Memberships
- Fellow
